Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics director Jonathan D. Root received a grant of stock options to acquire 16,377 shares of common stock on June 5, 2026. The options have an exercise price of $35.5900 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of shareholders, and Root now directly holds options for 16,377 shares from this grant.
Edgewise Therapeutics, Inc. completed the sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals LLC and Les Laboratoires Servier, receiving $1.55 billion in upfront cash and eligibility for up to $1.1 billion in additional regulatory and commercial milestones, for total potential consideration of $2.65 billion. The disposed assets are treated as a sale of nonfinancial assets under U.S. GAAP and do not qualify as discontinued operations. Edgewise has prepared unaudited pro forma condensed financial information under Article 11 of Regulation S-X to illustrate the effects.
Pro forma as of March 31, 2026, cash and cash equivalents rise to about $1.53 billion, total assets to $2.01 billion, and stockholders’ equity to roughly $1.75 billion, driven by an estimated pre-tax gain of $1,487,621 thousand and after-tax gain of $1,261,765 thousand. For 2025, pro forma results show net income of $1,135,527 thousand and earnings per share of $11.03, compared with a historical net loss of $167,795 thousand and a loss per share of $(1.63). For the three months ended March 31, 2026, the pro forma net loss is $27,937 thousand versus a historical loss of $49,013 thousand, reflecting removal of sevasemten-related expenses.
A Transition Services Agreement requires Edgewise to provide specified services to Servier at below-market rates; $17,880 thousand of consideration is allocated to this obligation and recorded as deferred income, with $5,364 thousand current and $12,516 thousand non-current, recognized in other income as services are performed. The pro forma statements present TSA costs in operating expenses and Servier reimbursements plus deferred income amortization in other income, with no net effect on pro forma earnings for the periods shown.
Edgewise Therapeutics, Inc. completed the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals and Les Laboratoires Servier. Servier acquired all related rights and assets for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.
Edgewise states that the transaction strengthens its balance sheet, enhances financial flexibility, and aligns with a strategy to focus on its cardiovascular pipeline, including EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. Upfront proceeds, together with existing cash, are expected to fully fund EDG-7500 development through potential approval.
Edgewise Therapeutics, Inc. reported that Chief Scientific Officer Alan J. Russell executed an exercise-and-sell transaction involving company stock. He exercised stock options to acquire a total of 200,000 shares of common stock, including 69,648 shares at an exercise price of $0.18 per share and 130,352 shares at an exercise price of $0.45 per share. On the same date, he sold 69,648 shares at an average price of $39.4089 per share and 130,352 shares at an average price of $39.4060 per share in open-market transactions, for total sales of 200,000 shares. Following these transactions, he directly holds 94,203 shares of common stock and retains 1,077,717 stock options with a $0.18 exercise price expiring on June 27, 2032.
Fox Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
Edgewise Therapeutics director Jonathan C. Fox received a grant of 319 shares of Common Stock. The shares were awarded at a price of $0.00 per share as a compensation-related grant, not an open-market purchase. Following this award, Fox directly holds 24,833 shares of Edgewise Therapeutics common stock.
Edgewise Therapeutics director Laura Brege received a new stock option grant covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day before the 2027 annual meeting of stockholders.
After this grant, Brege holds 16,377 stock options directly, all tied to this award.
Edgewise Therapeutics director and 10% owner Peter A. Thompson received a grant of stock options for 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036.
According to the terms, 100% of these options will vest on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. Following this grant, Thompson holds 16,377 stock options directly.
Edgewise Therapeutics director Arlene Morris received a grant of stock options covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the terms, 100% of these options will vest on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. Following this grant, Morris holds stock options for 16,377 underlying shares directly.
Edgewise Therapeutics, Inc. director Edris Badreddin received new equity-based compensation. On June 5, 2026, he was granted stock options for 8,188 shares of common stock at an exercise price of $35.59 per share, expiring on June 5, 2036. He also received 5,619 Restricted Stock Units (RSUs). According to the terms, 100% of both the options and RSUs will vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of stockholders. These are compensation grants, not open‑market purchases or sales.